New urine test could spot bladder tumors more accurately

NCT ID NCT06072027

Completed Diagnosis Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a new urine test called VISIOCYT can better detect bladder tumors than standard methods. Over 700 patients undergoing cystoscopy (a scope procedure) provided urine samples for both standard and VISIOCYT analysis. The goal was to see how accurate the new test is at ruling out cancer and catching it when present.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VISIOCYT bladder cytology test
What this could lead to: If successful, this test could offer a more accurate, non-invasive way to detect or monitor bladder tumors, potentially reducing the need for invasive procedures.
What could go wrong: This is a completed observational study, not a treatment trial. The test may not prove more accurate than standard cytology, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Institut Paoli-Calmettes

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.